Deep venous thrombosis is perhaps the single most significant preventable cause of morbidity and mortality in the neurosurgical patient population nowadays. Although the lack of a standard definition for DVT (for example, clinically silent or symptomatic) and differing screening methods make interpretation of the current research findings difficult, average estimates place the incidence of DVT at approximately 25% in patients who undergo neurosurgery. In isolation DVT is not a life-threatening disorder, but in 1.5 to 5% of patients with this condition PE will develop, and PE is fatal in as many as 50% of these cases.

Prevention protocols for DVT have been widely discussed in the neurosurgical literature, but disagreement remains about the safety and effectiveness of these strategies. Many neurosurgeons fear the use of anticoagulating agents following intracranial surgery because of the risk of intracerebral hemorrhage. Others believe that mechanical compression is not effective enough as the sole preventive therapy. A lack of standardized research methods is partly to blame for the persisting debate. In this brief review, we discuss the pathophysiological features of DVT and summarize findings in the current literature with regard to epidemiological and pathophysiological features, screening methods, and prophylactic measures for DVT.

**KEY WORDS** • craniotomy • deep venous thrombosis • heparin • neurosurgery • pulmonary embolism

Deep venous thrombosis is perhaps the single most significant preventable cause of morbidity and mortality in the neurosurgical patient population nowadays. Although the lack of a standard definition for DVT (for example, clinically silent or symptomatic) and differing screening methods make interpretation of the current research findings difficult, average estimates place the incidence of DVT at approximately 25% in patients who undergo neurosurgery. In isolation DVT is not a life-threatening disorder, but in 1.5 to 5% of patients with this condition PE will develop, and PE is fatal in as many as 50% of these cases.

Prevention protocols for DVT have been widely discussed in the neurosurgical literature, but disagreement remains about the safety and effectiveness of these strategies. Many neurosurgeons fear the use of anticoagulating agents following intracranial surgery because of the risk of intracerebral hemorrhage. Others believe that mechanical compression is not effective enough as the sole preventive therapy. A lack of standardized research methods is partly to blame for the persisting debate. In this brief review, we discuss the pathophysiological features of DVT and summarize findings in the current literature with regard to the diagnosis, screening, and prevention of this perioperative killer.

**EPIDEMIOLOGICAL FINDINGS**

Although there is a great deal of variation in the statistics with regard to the overall incidence of DVT, all of the reported figures are quite high. In 1984 Coon estimated that more than 250,000 symptomatic DVTs are diagnosed in the US each year. Because symptomatic thromboses represent only a portion of the total incidence of DVT, Coon used the incidence of PE as a marker for DVT and extrapolated back to determine that the overall incidence of DVT is between 1.8 and 3 million cases per year. In a more recent study, researchers found a similar number of symptomatic DVTs and calculated that DVT-related PE is the direct cause of more than 100,000 deaths annually in hospitals in the US.

It is widely accepted that neurosurgical patients are at high risk for DVT when compared with other surgical and medical patient populations. The mean incidence of DVT in neurosurgical reports approaches 25%, depending on the study’s methodology. The incidence of PE is thought to be between 1.5 and 3%, with a mortality rate between 9% and 50%.

Factors that place neurosurgical patients at high risk for DVT can be separated into clinical risk factors, which are related to the patient’s physical status, and biological risk factors, which are unique to the underlying neuropathological features.

**Clinical Risk Factors**

General clinical risk factors for the development of DVT and PE include older age, heart failure, previous episodes of DVT, obesity, and malignancy, and these factors are present in much of the neurosurgical patient population. In addition to these general factors, a number of clinical risk factors specific to the neurosurgical population have been identified. In a study of 443 patients undergoing craniotomy, Macdonald, et al., observed that the factors that increased the risk of development of DVT included the presence of preoperative leg weakness, longer pre- and postoperative intensive care unit stays, prolonged hospital stay, prolonged recovery room time, and delayed initiation of mobility and activity.
Other investigators have confirmed these factors, emphasizing the importance of extremity paresis and also the significant increase in DVT risk following craniotomy as opposed to spinal surgery (Table 1).8,51 Bostrom, et al.,8 examined the influence of both paresis and surgery site on the incidence of DVT and found that DVT occurred in 14% of patients without paresis who underwent craniotomy and in none of the patients without paresis who underwent spinal surgery. In patients with lower-limb paresis postsurgery, the incidence of DVT was 57% after intracranial surgery and 14% after spinal surgery. The neurosurgical literature has even mentioned factors such as race as having an effect on the incidence of DVT. In one screening study, researchers found that the incidence of DVT was 4% in Chinese patients who underwent craniotomy, and the incidence in a non-Chinese matched population was 10 to 15%. The authors hypothesized that these findings may be due to a difference in the prevalence of activated protein C resistance between the two populations.44

It should be noted that our review is focused on perioperative DVT and therefore a discussion of patient populations such as those with stroke and spinal cord injury is not included. The nature and chronicity of these conditions places patients at extraordinarily high risk for DVT; the rate is as high as 76% in patients with stroke and 100% in patients with spinal cord injury according to follow-up studies.32,46,60

**Biological Risk Factors**

There has been an attempt to elucidate the biological mechanisms that place craniotomy patients at high risk for DVT; however, the specific mechanisms have yet to be demonstrated. Most of the research focuses on patients with brain tumors, a subpopulation that has been found to have perhaps the greatest risk of DVT of all patients who undergo neurosurgery.

Coagulation abnormalities have been identified that are believed to play a role in DVT. These include elevations in fibrinopeptide A and fibrinogen fragment Bβ15-42; decreased activated partial thromboplastin time and increased fibrinopeptide A levels; and subclinical disseminated intravascular coagulation.32 Tissues obtained in patients with intracranial tumors who experienced thromboembolic events have been shown to have an imbalance of plasminogen activator and inhibitor systems.37 More specifically, brain tumors have been found to inhibit plasmin, enhance release of thromboplastin, and increase procoagulant and platelet aggregatory activity.15 In a study of 114 patients with brain tumors, Sawaya, et al.,56 found that total fibrinolytic activity was reduced in patients with malignant brain tumors. Plasminogen and plasmin inhibitor levels did not show significant changes, but tissue plasminogen activator was low and plasminogen activator inhibitor–1 levels were high in a large proportion of patients.

The overall risk that a patient with a brain tumor will display a DVT on follow-up studies is reported to be between 22 and 45%.55,59,61,66 Clearly, as mentioned in the previous section, clinical factors specific to patients with tumors, such as supratentorial and suprasellar locations, increase risk.19 In addition to these clinical factors, there is evidence that biological factors such as tumor histological features may define different levels of DVT risk. Sawaya, et al.,56 found that the incidence of DVT in patients with meningiomas, malignant glioma, and metastatic disease was 72, 60, and 20%, respectively. In studies by Missori, et al.,44 and Levi, et al.,39 these investigators also noted that meningiomas seem to carry the highest risk of DVT of all intracranial tumors, especially when the lesions are in close contact with a venous sinus.

Unfortunately, data such as these are purely observational, and to date there is little in the way of a mechanistic explanation for these pathological associations. Perhaps the greatest contributor to the reported variation of DVT risk among patients with brain tumors is the degree of clinical attentiveness. The incidence of clinical DVT appears to be much higher in series in which the focus was thromboembolic complications of tumors; in more general brain tumor series much lower DVT rates are reported, as is evident from Table 2.

Chemotherapeutic agents used to combat brain tumors have also been linked to increased DVT risk. Specifically.

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Risk factors for thromboembolism in patients who undergo craniotomy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General</strong></td>
</tr>
<tr>
<td>age &gt;60 yrs</td>
</tr>
<tr>
<td>history of DVT</td>
</tr>
<tr>
<td>duration of op procedure</td>
</tr>
<tr>
<td>prolonged immobilization</td>
</tr>
<tr>
<td>central line</td>
</tr>
<tr>
<td>use of oral contraceptive pills</td>
</tr>
</tbody>
</table>
| heart failure                                                 | total fibrinopeptide A and fibrino-
| deficiency                                                   | gen fragment Bβ15-42               |
| antithrombin III                                              | decreased activated partial tho-
| protein C or S                                                | mboplastin time                    |
|                                                               | increased fibrinopeptide A levels  |

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No. of Patients</th>
<th>No. w/ Clinical DVT (%)</th>
<th>Clinical PE</th>
<th>No. (%)</th>
<th>No. of Deaths</th>
<th>Brain Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomita &amp; Raimondi, 1981</td>
<td>80</td>
<td>NR</td>
<td>3 (3.8)</td>
<td>0</td>
<td>NR</td>
<td>glioma</td>
</tr>
<tr>
<td>Ruff &amp; Posner, 1983</td>
<td>264</td>
<td>66 (25.0)</td>
<td>NR</td>
<td>NR</td>
<td>0</td>
<td>glioma</td>
</tr>
<tr>
<td>Fadul, et al., 1988</td>
<td>213</td>
<td>5 (2.3)</td>
<td>3 (1.4)</td>
<td>0</td>
<td>glioma</td>
<td></td>
</tr>
<tr>
<td>Cheruku, et al., 1991</td>
<td>77</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>malignant glioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constantini, et al., 1991</td>
<td>633</td>
<td>23 (3.6)</td>
<td>19 (3.0)</td>
<td>7</td>
<td>all</td>
<td></td>
</tr>
<tr>
<td>Levi, et al., 1991</td>
<td>1703</td>
<td>17 (1.0)</td>
<td>10 (0.6)</td>
<td>0</td>
<td>all</td>
<td></td>
</tr>
<tr>
<td>Wilson, 1993</td>
<td>1771</td>
<td>30 (1.7)</td>
<td>17 (1.0)</td>
<td>8</td>
<td>all</td>
<td></td>
</tr>
<tr>
<td>Cabantog &amp; Bernstein, 1994</td>
<td>207</td>
<td>5 (2.4)</td>
<td>1 (0.5)</td>
<td>1</td>
<td>all</td>
<td></td>
</tr>
<tr>
<td>total</td>
<td>4948</td>
<td>146/4688</td>
<td>53/4684</td>
<td>16/53</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* NR = not reported.
the use chemotherapy regimens that include either 1,3-bis(2-chloroethyl)-1-nitrosourea or cisplatin increase the risk of DVT and PE.\textsuperscript{45}

**Screening Methods for DVT**

One reason the published incidences vary as much as they do could be the inconsistencies in study methodologies rather than true biological variation. Authors of various studies have chosen different definitions of what they believe to be a clinically relevant DVT, and they have also used screening methods with significantly different sensitivities.

Clinically, calf-vein thrombi are relatively benign unless they extend into the proximal veins. Most proximal-vein DVTs do not propagate out of the calf veins but form de novo in the major axial venous segments. Isolated calf-vein thrombi result in pulmonary emboli in less than 1% of cases, whereas thrombi in the proximal veins result in pulmonary emboli 40 to 50% of the time.\textsuperscript{30,40} Although most DVTs arise in the infrapopliteal veins, the major sources of emboli are proximal DVTs. Deep venous thromboses in the lower extremities are the source of 90% of pulmonary emboli, the remainder arise mostly from DVTs in the pelvis.\textsuperscript{31} Nevertheless, there are no studies in which the incidence of DVT in the upper extremities and the risk of PE in this patient population have been examined. Missori, et al.,\textsuperscript{44} found that in 88% of patients with pulmonary emboli the source lay in the proximal veins. Therefore, it may not be clinically necessary or efficient to scan routinely for calf-vein DVTs.

The presence of clinical symptoms of DVT is as unreliable a marker for this disease as their absence. The traditional clinical features, such as a swollen, tender, warm calf; venous dilation; or a positive Homans sign, are associated with proven DVT in only 20 to 50% of patients. Conversely, 50 to 60% of patients with DVT will not have these symptoms, a finding supported by the substantial number of those with PE who present with no clinical evidence of DVT.\textsuperscript{31}

**The $^{125}$I-Labeled Fibrinogen Test.** Several DVT screening tests are available. One of these is the $^{125}$I-labeled fibrinogen test, in which radiolabeled fibrinogen is injected intravenously, where it becomes incorporated into any developing thrombus and is visible on scans. Using the $^{125}$I-labeled fibrinogen test to evaluate DVT reveals an incidence of 29 to 43%, with 10 to 17% of these thrombi confirmed by other methods.\textsuperscript{19,66} Levi, et al.,\textsuperscript{39} reported that the technique had a positive predictive value of only 66%, with an overall accuracy of 70%. In one study a false-positive rate of 24% was reported when the findings on $^{125}$I-labeled fibrinogen scans were confirmed by other methods.\textsuperscript{41} In addition, radiolabeled fibrinogen scanning was found to be inaccurate for detection of clots originating in the pelvis and thigh, which are thought to be the most life-threatening types.

**Impedance Plethysmography.** A second method for diagnosing DVT is impedance plethysmography; this is the indirect assessment of blood-volume changes in any part of the body by measurement of the blood’s electrical impedance. Because blood is a good conductor of electricity, blood-volume changes in any part of the body are reflected inversely in the electrical impedance of the particular body segment. A continuous uniform flow of blood produces no significant change in the electrical impedance of the body segment, whereas pulsatile blood-volume changes are recorded as electrical impedance changes over time. With this technique practitioners can monitor the decreasing electrical impedance that blood produces as it leaves the calf veins through the proximal leg veins after relaxation of a pneumatic tourniquet. With obstruction of the proximal veins by a thrombus, the egress of blood from the calf and therefore the results of impedance plethysmography are abnormal.\textsuperscript{33} One of the advantages of this modality is that it is relatively easy to perform and there is very little inter- or intraobserver variation. Moreover, the risk of PE in patients with negative results on serial impedance plethysmography evaluations is less than 1%. Because false-negative findings can occur as the result of nonocclusive proximal DVT and in patients with well-developed collateral vessels, a negative finding on impedance plethysmography must be repeated over at least a 2-week period.\textsuperscript{31}

**Doppler Ultrasonography.** Doppler ultrasonography is the third major diagnostic test for DVT. This test is based on the same principle as impedance plethysmography; it detects the abnormal egress of blood from the calf when a thrombus is present. Doppler ultrasonography is noninvasive and painless. The addition of real-time B-mode imaging allows the venous anatomy, clot structure, and blood flow to be visualized. The accuracy of Doppler scanning in the diagnosis of DVT has been well documented, especially for proximal DVT, for which a sensitivity and specificity of more than 90% has been achieved.\textsuperscript{62,71} Some advantages over impedance plethysmography include the ability to perform the test in patients who are immobilized and in those who have lower leg casts or amputations. In addition, ultrasonography is more readily available in most treatment centers. The major disadvantage is that data interpretation can be highly subjective and requires a high level of skill, which is not the case with impedance plethysmography.\textsuperscript{33}

**Venography.** Although it is invasive, venography remains the definitive diagnostic test for DVT. Using fluoroscopy and a contrast dye, venography provides a dynamic and detailed image of the leg veins. It is extremely sensitive in identifying the location, extent, and degree of attachment of a clot. Rossi, et al.,\textsuperscript{50} state that venography remains the only reliable diagnostic method for DVT detection in patients who are asymptomatic postoperatively, but that it is not a practical screening test. Venography exposes the patient to radiation, it is painful, and it takes approximately 30 to 45 minutes to perform. The test also carries the risk of allergic reactions and renal dysfunction, and may actually produce a new DVT in approximately 1% of cases.\textsuperscript{64} Additionally, good interobserver agreement has been difficult to achieve.\textsuperscript{33}

**Strategies for DVT Prophylaxis**

The methods used for pericraniotomy DVT prophylaxis are mechanical, pharmacological, or a combination of both.
Mechanical. These techniques include the use of graduated compression stockings, electrical stimulation of the calf muscles, intermittent external pneumatic calf compression, and rotating tables. The main advantages of mechanical prophylaxis are that there is minimal risk associated with them, and they are relatively inexpensive and simple to use.25

Both local and systemic factors appear to be involved in the success of mechanical prophylaxis. Elastic support of 16 to 20 mm Hg decreases venous stasis and increases venous return. Leg wrappings and stockings with no pressure gradient are ineffective in the prevention of DVT.10 The period of “fibrinolytic shutdown” after surgery appears to be reversed with intermittent calf compression.11 In one comparison of mechanical devices, Vaneck57 suggested that pneumatic compression was superior to stockings in preventing DVT but not PE, but admitted that the data were “sparse and conflicting.”

Pharmacological. Although several medications, including aspirin, unfractionated heparin, low-molecular-weight heparin, and warfarin have been used for pharmacological prophylaxis, heparin is the only one used perioperatively in patients undergoing neurosurgery. Heparin is a naturally occurring anticoagulant that is synthesized and secreted by mast cells in the body. It binds to antithrombin III and inhibits thrombogenesis, primarily through inactivation of factors IIa and Xa. Larger heparin fragments can also bind to and inactivate thrombin.

The low-molecular-weight heparins are fragments of unfractionated heparin with a shorter glycosaminoglycan chain length. This prevents them from binding to protein, such as thrombin. Factor Xa is preferentially inhibited compared with unfractionated heparin, and because thrombin is unaffected the partial thromboplastin time is unchanged compared with unfractionated heparin, and because thrombin is unaffected the partial thromboplastin time is normal. Theoretical advantages of low-molecular-weight heparins are more predictable anticoagulant response, greater bioavailability and longer half-life when administered subcutaneously, lower incidence of heparin-induced thrombocytopenia, and less inhibition of platelet function.40

It is unclear when to start prophylaxis and how long to continue it. Some practitioners advocate 2 weeks of prophylaxis for all patients after surgery. They support this recommendation with studies indicating that the majority of acute clinically apparent DVTs are diagnosed during this time period, and it is also the time in which 75% of asymptomatic DVTs are believed to be formed.24 Others propose a longer duration of prophylaxis, observing that patients who remained at risk for DVT after 1 or 2 weeks experienced this condition at the same rate as control patients after mechanical prophylaxis was stopped. MacDonald, et al.,41 reported that in 50% of patients in whom DVT developed, it occurred between 1 and 2 months post-surgery.

Whether heparin should be started intraoperatively or at some early point post-surgery has not been determined. Given that bleeding after craniotomy may result in devastating complications, many practitioners wait at least 1 day after surgery to begin heparin administration.21 Waiting to begin heparin treatment until the early postoperative period does not appear to increase the rate of DVT formation. MacDonald, et al., studied patients in the initial days after surgery and did not detect a single DVT in more than 100 patients examined using Doppler ultrasonography within 2 or 3 days of the procedure.

Comparison of Prophylactic Strategies

Comparing studies of venous thromboembolism prophylaxis is difficult for several reasons: 1) the studies vary in the method used to diagnose venous thromboembolism; 2) there is marked variability in the types of patients studied; and 3) the number of patients in the studies is often small, making it difficult to perform any reliable statistical analysis on the results.67

In 1986, the participants in the National Institutes of Health Consensus Conference recommended mechanical DVT prophylaxis methods for patients undergoing craniotomy for tumor, subarachnoid hemorrhage, arteriovenous malformations, shunt placement, and other intracranial procedures. They recommended pharmacological prophylaxis only in patients undergoing extracranial procedures.4

Although investigators in a study in which leg venography with contrast enhancement was used found that patients receiving prophylaxis only with compression stockings had a DVT rate of 32%,2 most other researchers have reported much lower rates. Intermittent pneumatic compression has been shown to be effective in reducing the incidence of DVT from 23 to 6%, a risk reduction of 74%. The apparent incidence of DVT is lower when screening is performed using radioactive fibrinogen scanning.1 In one metaanalysis, intermittent pneumatic compression was found to provide a 63% risk reduction for DVT and a 49% risk reduction for PE.67 Perhaps the most important incidences of thromboembolism are those associated with clinically diagnosed DVT and PE. In Table 3 we summarize the incidence of DVT and PE among patients receiving mechanical prophylaxis compared with those who receive no preventive treatment.

Graduated knee-high or thigh-high compression stockings have been reported by some investigators to be as effective as intermittent pneumatic compression in preventing DVT.66,67 There are studies in which intermittent pneumatic compression has been applied only to one leg, with the other being used as a control. In the treated leg there was a 3% incidence of DVT, whereas its incidence in the control leg was 24%.67 The investigators concluded...

| Table 3 | Studies showing risk of thromboembolism with mechanical prophylaxis alone postcraniotomy |
| --- | --- | --- | --- |
| Prophylaxis | Reference Pop (no.) | Weighted Mean (%) for Complication |
| none | 2670 | 4.3 | 1.40* |
| mechanical | 2949 | 1.42 | 0.68 |

* Pop = population.
† Not all of the studies in this subgroup specified the incidence of PE.
that intermittent compression of one leg was not protective against DVT in the other one.

Mechanical prophylaxis provides a well-documented benefit in the prevention of DVT, and at most only theoretical risks of fibrinolysis and clot dislodgement. It is widely accepted that every patient should receive some form of mechanical prophylaxis. There are some advantages to compression stockings, such as ease of application and better patient compliance. Nevertheless, there is inadequate information to determine whether stockings are as effective as pneumatic compression boots. In 2001, Cupitt reported that 90% of neurosurgical units used graduated compression stockings instead of intermittent pneumatic compression devices. Mechanical techniques offer adequate prophylaxis for low- and moderate-risk patients, but may be suboptimal with higher-risk individuals.

Cerrato, et al., randomized 100 craniotomy patients to a control group and a heparin recipient group and found that heparin decreased the rate of DVT detected using radiolabeled fibrinogen to 6%, compared with 34% in the control group. In this and most other trials discussed in the present study, the control group received mechanical prophylaxis only. Macdonald and colleagues conducted a study in which perioperative subcutaneous heparin was used in 106 patients; these authors stated that heparin may be safe to administer to patients undergoing craniotomy, but that a larger study was needed to demonstrate efficacy. Constantini, et al., reported that the incidence of clinically evident DVT was 2.3 to 19%, with a 3.9% incidence of PE. In addition, they concluded that minidoses of unfractionated heparin were safe to use in the perioperative period. Wen and Hall, in a series of 152 patients undergoing cranial procedures who were treated with twice-daily minidoses of heparin starting before surgery, observed only two episodes of major bleeding and concluded that this regimen was safe. In a recent review, Misra and associates examined more than 1000 neurosurgery intensive care unit admissions and found a 3% incidence of DVT on follow-up studies, and a 0.1% risk of PE. They concluded that a regimen of twice-weekly ultrasound scanning combined with low-dose unfractionated heparin was effective. Nevertheless, they failed to specify when prophylaxis was started or to stratify patients by diagnosis.

Because of the theoretical risk of hemorrhagic complications after therapy with unfractionated heparin, the use of low-molecular-weight heparins, which have less of an effect on antithrombin III and so maintain an antithrombotic effect with a limited anticoagulation effect, has been suggested for high-risk patients.

In a prospective trial conducted by Goldhaber, et al., 150 patients were assigned to groups receiving mechanical prophylaxis and either unfractionated heparin or enoxaparin. These authors found a 24% risk of DVT with enoxaparin and 13% with heparin. They concluded that enoxaparin did not demonstrate superior efficacy in preventing DVT or PE when compared to heparin. In a multicenter trial, 485 patients were randomly allocated to receive either nadroparin, a low-molecular-weight heparin, or graduated compression stockings. The relative short-term risk reduction for DVT in the treatment group was 28.9%. The investigators reported an insignificant trend toward increased major bleeding and mortality rates, but concluded that the benefit of using pharmacological prophylaxis outweighed the risks. In a smaller study of patients with brain tumors, enoxaparin treatment initiated at the time of surgery increased the risk of ICH, and the study was terminated early. Agnelli and associates randomized 307 patients and found that enoxaparin started the morning after surgery significantly reduced the risk of DVT without significantly increasing the risk of intracranial bleeding. Norwood, et al., evaluated the safety of enoxaparin prophylaxis in 150 patients with intracranial hemorrhagic injuries and concluded that this drug could be safely used when it was started 24 hours after admission or craniotomy.

Macdonald, et al., studied dalteparin, a low-molecular-weight heparin, comparing it with unfractionated heparin in a randomized trial of 100 patients. They found a 0% rate of DVT in the group treated with heparin, and a 2% risk of DVT in those treated with dalteparin. They concluded that both interventions were safe for prophylaxis. In a retrospective review of 150 patients in whom certoparin was used, the risk of DVT and PE was 0.2 and 0.1%, respectively. Table 4 summarizes the risk of DVT and PE when mechanical and pharmacological prophylaxis were combined.

**Risk of ICH With Pharmacological Prophylaxis**

Because of an understandable fear of complications from anticoagulation therapy, there remains a reluctance to use routine pharmacological prophylaxis. Stephens, et al., in a survey of 44 British neurosurgical units, found that only 32% used pharmacological prophylaxis perioperatively, and that this rate is reduced to 6% in units in which emergency neurosurgery is performed. The need for repeated intervention because of bleeding complications has been estimated to vary between 1 and 8%. Both unfractionated and low-molecular-weight heparin have been subject to scrutiny. Wen and Hall performed an analysis of the literature and found a hematoma rate of 1.2% in patients given unfractionated heparin, and a rate of 1.6% in those not treated in a total of 2400 patients. In a review of more than 1500 patients who underwent craniotomy and then received mechanical prophylaxis and low-molecular-weight heparin, Raabe, et al., observed a

<table>
<thead>
<tr>
<th>Prophylaxis</th>
<th>Reference Pop (no.)</th>
<th>Weighted Mean (%) for Complication</th>
<th>DVT</th>
<th>PE</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC + unfractionated heparin</td>
<td>3550</td>
<td>1.83</td>
<td>0.34</td>
<td>15,25,29,40, 41,52</td>
<td></td>
</tr>
<tr>
<td>PC + low-molecular-weight heparin</td>
<td>2004</td>
<td>0.50</td>
<td>0.15</td>
<td>3,22,29,38, 40,48</td>
<td></td>
</tr>
</tbody>
</table>

*PC = pneumatic compression.*

---

_Neurosurg. Focus / Volume 17 / October, 2004_
2% risk of hemorrhage requiring intervention. Paolotti, et al., treated 917 patients with fraxiparin, a low-molecular-weight heparin, and noted 19 postoperative hematomas, none of which required surgical evacuation. The risk of intracranial bleeding from nadroparin was found to be much higher compared with enoxaparin; 2.5% compared with 0.4%. In the largest series of craniotomies to date in which perioperative low-molecular-weight heparin was used for prophylaxis, a hemorrhage rate of more than 3% was observed; nevertheless, the authors concluded that the data supported its use. The risk of hemorrhage with and without heparin prophylaxis is summarized in Table 5. The sequelae of postoperative ICHs are bleak; on average more than 35% of patients are left with severe neurological deficits and 25% die.

CONCLUSIONS

Unfortunately, the literature provides little guidance on the most effective and safest means to prevent thromboembolic complications in patients who undergo craniotomy. Most investigators have concentrated on the incidence of DVT, as measured in follow-up studies. This approach fails to determine, however, whether DVTs discovered during follow-up examinations have the same impact as lesions that are associated with clinical findings such as leg swelling or pain. It also fails to consider the offsetting risks of ICH, the occurrence of which is bound to rise as heparin reduces the risk of DVT.

One might argue that a randomized, controlled clinical trial or metaanalysis in which two or all three treatment options could be compared would provide Class I evidence. However, when comparing prophylaxis, a hemorrhage rate of more than 3% was observed; nevertheless, the authors concluded that the data supported its use. The risk of hemorrhage with and without heparin prophylaxis is summarized in Table 5. The sequelae of postoperative ICHs are bleak; on average more than 35% of patients are left with severe neurological deficits and 25% die.

We are currently preparing a threshold analysis to assist individual surgeons and institutions in decisions about prophylactic measures in their patients who undergo craniotomy. Depending on the observed incidence of DVT, PE, and postoperative hemorrhage, the analysis can be used to predict whether the overall outcome will be better if heparin is added to pneumatic compression.

TABLE 5

<table>
<thead>
<tr>
<th>Prophylaxis</th>
<th>Reference Pop (no.)</th>
<th>Weighted Mean (%)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC only</td>
<td>31,725</td>
<td>1.11</td>
<td>3,6,13,14,18,22,23, 25–27,36,41,48, 49,54,63,64,72</td>
</tr>
<tr>
<td>PC + unfractionated heparin</td>
<td>1,922</td>
<td>1.87</td>
<td>5,8,14,18,25,29,40, 41,52,70</td>
</tr>
<tr>
<td>PC + low-molecular-weight heparin</td>
<td>2,025</td>
<td>3.16</td>
<td>3,22,29,38,40,48</td>
</tr>
</tbody>
</table>

References


Neurosurg. Focus / Volume 17 / October, 2004
Prophylaxis for DVT in patients with craniotomies: a review


60. Schmidt EV, Smirnov VE, Ryabova VS: Results of the seven-


Manuscript received June 15, 2004. Accepted in final form September 7, 2004. Address reprint requests to: Shabbar F. Danish, M.D., Department of Neurosurgery, Hospital of the University of Pennsylvania, Silverstein Building 3rd Floor, 3400 Spruce Street, Philadelphia, Pennsylvania 19104. email: Shabbardanish@hotmail.com.